Gilead Sciences (GILD) Tops Q1 EPS by 15c, Reiterate Guidance
Gilead Sciences (NASDAQ: GILD) reported Q1 EPS of $1.76, $0.15 better than the analyst estimate of $1.61. Revenue for the quarter came in at $5.3 billion versus the consensus estimate of $5.3 billion.
- Full Year 2019 Guidance Reiterated
Gilead reiterates its full year 2019 guidance, initially provided on February 4, 2019. The guidance for product sales reflects the anticipated entry of generic versions of Letairis and Ranexa in the United States and the full year impact of generic products containing tenofovir disoproxil fumarate in certain European countries.
| (In millions, except percentages and per share amounts) | � | Initially Provided February 4, 2019 |
| Net Product Sales | $21,300 - $21,800 | |
| Non-GAAP | ||
| Product Gross Margin | 85% - 87% | |
| R&D Expenses | $3,600 - $3,800 | |
| SG&A Expenses | $3,900 - $4,100 | |
| Effective Tax Rate | 20.0% - 21.0% | |
| Diluted EPS Impact of Acquisition-related, Up-front Collaboration, Stock-based Compensation and Other Expenses | $1.40 - $1.50 |
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.